Company came out with decent nos, with sales and profits growing at 11% in FY22. Management had an interaction with Zee business where they mentioned that the cephalosporin capacity will start in a month, which can contribute to 20-25% sales growth in FY23. Notes from interview is below.
20.05.2022 (Zee Business interview link)
- Production from expanded facility should start from June, most of the expansion is in tablet segment
- Expect 20-25% growth in FY23 (will be visible from Q2FY23)
Disclosure: Invested (position size here, bought shares today)